# Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

> **NCT01619813** · PHASE2 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 85 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel, Reolysin and Prednisone
- **DRUG:** Docetaxel and Prednisone

## Key facts

- **NCT ID:** NCT01619813
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-14
- **Primary completion:** 2016-04-26
- **Final completion:** 2016-05-20
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01619813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01619813, "Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01619813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*